MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-20-2026
Sintx Technologies Cost of Revenue 2011-2026 | SINT
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Sintx Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 557 K | 811 K | 784 K | 265 K | 449 K | 475 K | 551 K | 56 K | 6.35 M | 3.78 M | 6.25 M | 7.91 M | 7.04 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.91 M | 56 K | 2.71 M |
Quarterly Cost of Revenue Sintx Technologies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115 K | 94 K | 246 K | - | 210 K | 224 K | 223 K | - | 117 K | 104 K | 118 K | - | 89 K | 66 K | 80 K | - | 190 K | 73 K | 61 K | - | 53 K | 163 K | 166 K | - | 151 K | 133 K | 79 K | - | - | 521 K | 524 K | - | 1.41 M | 722 K | 661 K | - | 765 K | 1.02 M | 893 K | - | 1.64 M | 1.36 M | 1.52 M | - | 1.94 M | 1.6 M | 1.65 M | - | 1.74 M | 1.33 M | 1.95 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.95 M | 53 K | 631 K |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 11.1 | -0.72 % | $ 314 M |  USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Electromed
ELMD
|
14 M | $ 25.81 | 0.98 % | $ 218 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.16 | - | $ 1.31 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.45 | 3.29 % | $ 129 M |  France |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.61 | -2.42 % | $ 38 M | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 11.53 | 4.63 % | $ 413 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 57.59 | -2.51 % | $ 3.14 B |  Britain |
 |
LENSAR
LNSR
|
31.3 M | $ 5.48 | -1.44 % | $ 65.5 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Insulet Corporation
PODD
|
768 M | $ 167.53 | -2.25 % | $ 11.8 B | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 48.25 | -12.02 % | $ 1.42 B | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.05 | -3.23 % | $ 17.8 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 17.04 | 7.98 % | $ 400 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.82 | -0.52 % | $ 1.02 B | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
TransMedics Group
TMDX
|
243 M | $ 94.93 | -2.21 % | $ 3.23 B | USA |
 |
Tandem Diabetes Care
TNDM
|
469 M | $ 19.42 | -2.26 % | $ 1.32 B | USA |
 |
Globus Medical
GMED
|
958 M | $ 90.03 | -0.63 % | $ 12.2 B | USA |
 |
NanoVibronix
NAOV
|
2.4 M | - | - | $ 1.08 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 36.64 | 2.12 % | $ 1.14 B | USA |
 |
Stryker Corporation
SYK
|
9.05 B | $ 295.25 | 1.5 % | $ 113 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 85.85 | 2.26 % | $ 2.98 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 82.91 | -0.5 % | $ 48.5 B | USA |
 |
Pulmonx Corporation
LUNG
|
23.4 M | $ 1.27 | -4.51 % | $ 51.7 M | USA |
 |
MiMedx Group
MDXG
|
73 M | $ 3.64 | 0.83 % | $ 538 M | USA |
 |
Myomo
MYO
|
14 M | $ 0.88 | 1.69 % | $ 36.8 M | USA |